Author

C. S. McKimmie

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Approach:statistical model· 2 Organism:Arabidopsis· 1

Frequent Co-Authors

M. Pingen· 3 shared S. Griffin· 3 shared D. Lefteri· 2 shared F. Del Galdo· 2 shared G. Migneco· 2 shared G. P. Cook· 2 shared M. J. Bentham· 2 shared R. Foster· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

M. Pingen

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Inhibitors of the Small Membrane (M) Protein Viroporin Prevent Zika Virus Infection

E. Brown, G. Swinscoe, D. Lefteri, R. Singh, A. Moran, R. Thompson, D. Maskell, H. Beaumont, M. J. Bentham, C. Donald, A. Kohl, A. Macdonald, N. Ranson, R. Foster, C. S. McKimmie, , S. C. Griffin

This study identifies the ZIKV M protein as a therapeutic target, showing that inhibitors like rimantadine block viral infection in vitro and in vivo by targeting M-formed channels.

eLife · Aug 23, 2024Peer-reviewedMicrobiology

The Beta secretase BACE1 drives fibroblasts activation in Systemic Sclerosis through the APP/Beta-catenin/Notch signalling axis

C. W. Wasson, E. De Lorenzis, E. M. Clavane, R. L. Ross, K. A. Walker, B. Caballero-Ruiz, C. Antinozzi, R. Wells, G. Migneco, J. M. Y. Brown, N. A. Riobo-Del Galdo, L. Di Luigi, C. S. McKimmie, F. Del Galdo, P. J. Meakin

This study shows BACE1 drives fibroblast activation in systemic sclerosis via the APP/Beta-catenin/Notch axis and identifies BACE1 as a potential therapeutic target.

bioRxiv · Dec 22, 2022Immunology

Mosquito saliva sialokinin-dependent enhancement of arbovirus infection through endothelial barrier leakage

D. Lefteri, S. Bryden, M. Pingen, S. Terry, E. Beswick, G. Georgiev, M. Van Der Laan, V. Mastrullo, P. Campagnolo, R. M. Waterhouse, M. Varjak, A. Merits, R. Fragkoudis, S. Griffin, E. Pondeville, C. S. McKimmie

This study identifies sialokinin in Aedes mosquito saliva as a factor that enhances arbovirus infection by reducing endothelial barrier integrity, suggesting it as a therapeutic target.

bioRxiv · Feb 19, 2021Microbiology

The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patients

D. J. Payne, S. Dalal, R. Leach, R. Parker, S. Griffin, C. S. McKimmie, G. P. Cook, S. J. Richards, P. Hillmen, T. Munir, L. Arnold, K. Riley, C. McKinley, S. Place, R. L. Baretto, D. J. Newton

This study examines the role of the CXCR6/CXCL16 axis in severe COVID-19, finding elevated CD8+CXCR6+ T cells with age and increased CXCL16 levels in severe cases.

bioRxiv · Jan 25, 2021 · PreprintImmunology

A novel antiviral formulation inhibits a range of enveloped viruses.

N. F. Fletcher, L. W. Meredith, E. L. Tidswell, S. R. Bryden, D. Goncalves-Carneiro, Y. Chaudhry, C. Shannon-Lowe, M. A. Folan, D. A. Lefteri, M. Pingen, D. Bailey, C. S. McKimmie, A. W. Baird

This study evaluates a novel antiviral formulation, ViroSAL, which inhibits multiple enveloped viruses in vitro and in vivo by disrupting viral envelopes.

bioRxiv · Mar 29, 2020Microbiology

Targeting BDCA2 suppresses Plasmacytoid dendritic cell dependent interferon response and tissue fibrosis

R. L. Ross, C. Corinaldesi, G. Migneco, I. Carr, A. Antanaviciute, A. Carriero, C. Wasson, I. Georgiou, J. H. W. Distler, S. Holmes, Y. M. El-Sherbiny, C. S. McKimmie, F. Del Galdo

This study shows that targeting BDCA2 reduces pDC-driven interferon responses and fibrosis in preclinical models of skin inflammation.

bioRxiv · Jan 30, 2020 · PreprintImmunology

Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza

C. Scott, J. Kankanala, T. L. Foster, D. Goldhill, K. J. Simmons, M. Pingen, M. J. Bentham, E. Atkins, E.-A. Loundras, R. Elderfield, J. K. Claridge, J. Thompson, R. Stilwell, R. Tathineni, C. S. McKimmie, , S. Griffin

The paper identifies M2-N31 inhibitors that show synergistic antiviral effects when combined with existing drugs, offering a strategy to combat rimantadine-resistant influenza.

bioRxiv · Jul 24, 2019Microbiology